Blood pressure effects of the angiotensin II receptor blocker, losartan

What Was Tested

Researchers studied Angiotensin II in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults.

The study was performed in nonblack hypertensive patients whose baseline untreated clinical diastolic blood pressures were 95 mm Hg or higher and whose average 24-hour ambulatory diastolic blood pressures were 85 mm Hg or higher.

Clinical and 24-hour ambulatory blood pressures were measured at baseline (off treatment for at least 4 weeks) and after 4 weeks of treatment.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.

As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.

The timeline in the abstract includes 4 weeks.

What Was Measured

The subject headings attached to it are Angiotensin II, Angiotensin Receptor Antagonists, Antihypertensive Agents, Biphenyl Compounds, Blood Pressure, Imidazoles and Least-Squares Analysis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in people with low blood pressure and orthostatic hypotension over 4 weeks.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1995 (Archives of internal medicine), a journal based in United States.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.